Overactive Bladder Treatment Market Analysis

Overactive Bladder Treatment Market Analysis

To get key market trends

  Download Free Sample

Based on the condition type, the market is categorized into neurogenic bladder overactivity and idiopathic bladder overactivity. The idiopathic bladder overactivity segment is set to lead the market, generating the highest revenue of USD 2.8 billion, with projections to reach USD 4 billion by 2032.

• Idiopathic or non-neurogenic overactive bladder occurs when the nerve pathways in the bladder malfunction without an identifiable neurological cause. Therefore, addressing the global concern for bladder malfunction has led governments to focus on proactive approaches, ensuring more consistent and effective management of overactive bladder.

   

• For instance, the American Urological Association amended guidelines in September 2019 to provide a clinical framework for diagnosing and treating non-neurogenic overactive bladder. Thus, increasing government support for standardizing care practices to improve treatment outcomes is driving market growth.

Based on treatment type, the overactive bladder treatment market is classified into drug therapy, botox treatment, neuromodulation, and other treatment types. The drug therapy segment holds the largest market share of 48.9% in 2023 and is expected to maintain dominance throughout the analysis period.

• Drug therapies are widely prescribed due to their efficacy in managing overactive bladder symptoms. Mirabegron, a beta-3 adrenoceptor agonist available as an extended-release oral tablet that effectively manages symptoms such as urge urinary incontinence, urgency, and frequent urination is expected to spur the segmental growth.

   

• Additionally, regulatory support, exemplified by the FDA's approval for treating neurogenic detrusor overactivity in children, further bolsters segment growth.

   

Based on age group, the market is segmented into 18-30, 31-50, 51-60, and 60 above. The 51-60 age group segment is expected to exhibit CAGR of 4.2% during the analysis period.

• The 51-60 age group dominated the overactive bladder treatment industry driven by the higher prevalence of overactive bladder symptoms in this demographic.

   

• As people age, the incidence of conditions such as urgency, urinary incontinence, and frequent urination increases, leading to a greater demand for effective treatments. Also, this age group is more proactive in seeking medical assistance, contributing to the higher market share.

   

• Thus, the availability of advanced therapies and increased awareness pertaining to overactive bladder among individuals in this age range further support the market dominance.

The U.S. dominated the North American overactive bladder treatment market accounting for USD 1.4 billion in 2023 and is anticipated to show significant growth over the analysis period.

• The market growth is due to factors such as the rising prevalence of overactive bladder, presence of market key players and strong research and development background.

   

• For instance, Viatris Inc. is currently developing Onabotulinumtoxin A (botox) as a potential treatment for overactive bladder and cervical dystonia. The company aims to launch this product by 2026, subject to regulatory approvals. The introduction of this new therapy is expected to contribute to the growth of the OAB treatment.

   

• Thus, ongoing research activities and the availability of advanced treatment options, favorable reimbursement policies, and extensive healthcare infrastructure contribute to the U.S. market growth.

   

Germany exhibited a high growth potential in the European market.

• Germany is a key player in the overactive bladder treatment industry in Europe, with a strong healthcare infrastructure and a focus on innovative therapies.

   

• The country's market for overactive bladder treatment benefits from factors such as advanced medical research, a high prevalence of overactive bladder cases, and the presence of leading pharmaceutical companies.

   

• For instance, according to the German Continence Society, over 10 million people in Germany are affected by urinary incontinence, a common symptom of an overactive bladder. The substantial increase in cases has driven the demand for effective treatment options, thereby fueling the expansion of the market in Germany.

   

• In addition, the country's robust pharmaceutical industry and emphasis on research and development drive innovation and market expansion in overactive bladder treatment.

   

Asia Pacific overactive bladder treatment market is poised for rapid growth with a CAGR of 4.7% during the forecast period.

• The Asia Pacific region presents significant growth opportunities in the market owing to factors such as rising healthcare infrastructure development and increasing awareness about urinary disorders.

   

• The increasing prevalence of overactive bladder across the region is anticipated to bolster the demand for overactive bladder medications and treatments, thereby supporting the regional market.

   

• Additionally, the proliferation of product launches and the presence of numerous industry participants contribute to the regional market's growth. For instance, in November 2021, Taiho Pharmaceutical Co., Ltd. launched BUP-4 LADY, an over-the-counter (OTC) drugs for urinary urgency in Japan. This product was introduced in non-dispensing pharmacies, drug stores, and dispensing pharmacies across Japan. Hence, the increasing number of product launches and expanding research endeavors are expected to propel significant growth in the region in the coming years.